Angiogenic growth factor expression, including VEGF, has been previously reported in a variety of sarcomas and in GCT of bone [16-23], providing a rationale for the potential role of therapy directed against the VEGF signaling pathway, such as bevacizumab, in sarcomas, including GCT. The gene discussed is VEGFA; the disease is sarcoma.